Which is a Better Treatment for Hypertensive Patients with Diabetes: A Combination of Losartan and Hydrochlorothiazide or a Maximum Dose of Losartan?

REFERENCES

• Kannel WB, Wilson PW, Zhang TJ. The epidemiology of impaired glucose tolerance and hypertension. Am Heart J 1991; 121:1268–1273.
   PubMed Web of Science ®Google Scholar
• Cooper-DeHoff RM, Egelund EF, Pepine CJ. Blood pressure lowering in patients with diabetes—one level might not fit all. Nat Rev Cardiol 2011; 8:42–49.
   PubMed Web of Science ®Google Scholar
• Epstein M, Sowers JR. Diabetes mellitus and hypertension. Hypertension 1992; 19:403–418.
   PubMed Web of Science ®Google Scholar
• Japanese Society of Hypertension Committee. Guideline for Management of Hypertension (JSH 2009). Tokyo: Life Science Publishing Co., Ltd.; 2009:60–62.
   Google Scholar
• The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Guidelines for the management of arterial hypertension. Eur Heart J 2007; 28:1462–1536.
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003; 42:1206–1252.
   PubMed Web of Science ®Google Scholar
• ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981–2997.
   PubMed Web of Science ®Google Scholar
• Carlsen JE, Køber L, Torp-Pedersen C, Johansen P. Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. BMJ 1990; 300:975–978.
   PubMed Web of Science ®Google Scholar
• Harper R, Ennis CN, Heaney AP, A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM. Diabetologia 1995; 38:853–859.
   PubMed Web of Science ®Google Scholar
• Committee for Development of the Diabetes Clinical Practice Guidelines Based on Scientific Evidence. In: The Japan Diabetes Society, eds. Diabetes Clinical Practice Guidelines Based on Scientific Evidence 2010. Edited by the Japan Diabetes Society. Tokyo: Nankodo; 2010: 161–166 (in Japanese).
   Google Scholar
• The Japanese Society of Hypertension and Guidelines Subcommittee of Japanese Society of Hypertension. Guidelines for the Management of Hypertension. Tokyo: Life Science Publishing Co., Ltd., 2004.
   Google Scholar
• Matsuo S, Imai E, Horio M, Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53:982–992.
   PubMed Web of Science ®Google Scholar
• Bakris GL, Toto RD, McCullough PA, Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int 2008; 73:1303–1309.
   PubMed Web of Science ®Google Scholar
• Sawayama Y, Mukae H, Okada K, Use of the combination of losartan and hydrochlorothiazide in patients with essential hypertension. Prog Med 2011; 31:1293–1298 (in Japanese).
   Google Scholar
• Holdaas H, Hartmann A, Berg KJ, Renal effects of losartan and amlodipine in hypertensive patients with non-diabetic nephropathy. Nephrol Dial Transplant 1998; 13:3096–3102.
   PubMed Web of Science ®Google Scholar
• Gansevoort RT, de Zeeuw D, Shahinfar S, Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease. J Hypertens 1994; 12(Suppl):S37–S42.
   Google Scholar
• Lozano JV, Llisterri JL, Aznar J, Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics. Nephrol Dial Transplant 2001; 16(Suppl 1):85–89.
   PubMedGoogle Scholar
• Toto R, Shultz P, Raij L, Efficacy and tolerability of losartan in hypertensive patients with renal impairment. Collaborative Group. Hypertension 1998; 31:684–691.
   PubMed Web of Science ®Google Scholar
• Brenner BM, Cooper ME, de Zeeuw D, Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861–869.
   PubMed Web of Science ®Google Scholar
• Chiang CE, Wang TD, Li YH, Hypertension Committee of the Taiwan Society of Cardiology. 2010 guidelines of the Taiwan Society of Cardiology for the management of hypertension. J Formos Med Assoc 2010; 109:740–773.
   PubMed Web of Science ®Google Scholar
• Weiner DE, Tighiouart H, Elsayed EF, Uric acid and incident kidney disease in the community. J Am Soc Nephrol 2008; 19:1204–1211.
   PubMed Web of Science ®Google Scholar
• Nakashima M, Uematsu T, Kosuge K, Kanamaru M. Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 1992; 42:333–335.
   PubMed Web of Science ®Google Scholar
• Alderman M, Aiyer KJ. Uric acid: role in cardiovascular disease and effects of losartan. Curr Med Res Opin 2004; 20:369–379.
   PubMed Web of Science ®Google Scholar
• Liberopoulos E, Christides D, Elisaf M. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricemia and gout. J Hypertens 2002; 20:347.
   PubMed Web of Science ®Google Scholar
• Hamada T, Ichida K, Hosoyamada M, Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients. Am J Hypertens 2008; 21:1157–1162.
   PubMed Web of Science ®Google Scholar
• Franse LV, Pahor M, Di Bari M, et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). J Hypertens 2000; 18:1149–1154.
   PubMed Web of Science ®Google Scholar
• Bakris G, Molitch M, Hewkin A, Differences in glucose tolerance between fixed dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 2006; 29:2592–2597.
   PubMed Web of Science ®Google Scholar
• Shafi T, Appel LJ, Miller ER 3rd, Klag MJ, Parekh RS. Changes in serum potassium mediate thiazideinduced diabetes. Hypertension 2008; 52:1022–1029.
   PubMed Web of Science ®Google Scholar
• Eriksson JW, Jansson PA, Carlberg B, Hydrochlorothiazide, but not candesartan, aggravates insulin resistance and causes visceral and hepatic fat accumulation: the mechanisms for the diabetes preventing effect of candesartan (MEDICA) Study. Hypertension 2008; 52:1030–1037.
   PubMed Web of Science ®Google Scholar
• Zillich AJ, Garg J, Basu S, Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension 2006; 48:219–224.
   PubMed Web of Science ®Google Scholar
• Franco V, Oparil S. Salt sensitivity, a determinant of blood pressure, cardiovascular disease and survival. J Am Coll Nutr 2006; 25:247S–255S.
   PubMed Web of Science ®Google Scholar
• Glover M, Zuber AM, O’Shaughnessy KM. Hypertension, dietary salt intake, and the role of the thiazide-sensitive sodium chloride transporter NCCT. Cardiovasc Ther 2011; 29:68–76.
   PubMed Web of Science ®Google Scholar
• Otsuka R, Kato Y, Imai T, Decreased salt intake in Japanese men aged 40 to 70 years and women aged 70 to 79 years: an 8-year longitudinal study. J Am Diet Assoc 2011; 111:844–850.
   PubMed Web of Science ®Google Scholar
• Tomonari T, Fukuda M, Miura T, Is salt intake an independent risk factor of stroke mortality? Demographic analysis by regions in Japan. J Am Soc Hypertens 2011; 5:456–462.
   PubMed Web of Science ®Google Scholar
• Anderson CA, Appel LJ, Okuda N, Dietary sources of sodium in China, Japan, the United Kingdom, and the United States, women and men aged 40 to 59 years: the INTERMAP study. J Am Diet Assoc 2010; 110:736–745.
   PubMed Web of Science ®Google Scholar